Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PLTR$173.00-11.11(-6.03%)Palantir: 3 Key Takeaways for Long-Term Investors12:44:59 AM ETGS$901.00+4.17(+0.47%)Goldman Sachs raises 2027 Europe gas price forecasts on MidEast supply, winter risks12:09:21 AM ETGOOGL$280.40-0.85(-0.30%)ANALYSIS -AI-related debt binge may pressure European bond markets12:00:01 AM ETMS$185.73+1.43(+0.78%)BREAKINGVIEWS-Morgan Stanley is a dubious saviour for UBS12:00:00 AM ETCRM$226.00-3.17(-1.38%)Massive News for Salesforce Stock Investors11:45:02 PM ETARM$197.01-8.96(-4.35%)Why Arm Holdings Stock Lost 29% Last Month11:18:59 PM ETORCL$119.50-11.17(-8.55%)UPDATE 6-Oracle taps investors for $20 billion to finance AI expansion10:58:17 PM ETSKHY$148.53-0.68(-0.46%)Samsung and SK Hynix stocks plunge as a $20 billion AI shock rattles markets10:39:42 PM ETC$123.30+0.46(+0.38%)Japanese, Korean, Taiwanese firms' US investment set to keep climbing: Citi10:38:12 PM ETKO$95.96+1.88(+2.00%)Coca-Cola Is Exercising its Pricing Power as Inflation Persists10:35:02 PM ETGOOG$279.21+0.99(+0.36%)Google takes Dreambeans to India in bid to bring AI-generated personal stories to the masses10:30:00 PM ETORCL$119.50-11.17(-8.55%)BRIEF-Oracle Prices $20 Billion Of Common Stock And Senior Notes10:16:41 PM ETORCL$119.50-11.17(-8.55%)Oracle Announces Pricing of $20 Billion of Common Stock and Senior Notes10:10:08 PM ETPLTR$173.00-11.11(-6.03%)Palantir Technologies Inc. (PLTR) Q3 2026 Earnings Call Transcript10:08:30 PM ETIUSG$181.79-1.75(-0.95%)IUSG: Hyperscaler Sell-Off Is Overblown - Buy The Dip9:19:55 PM ETAAPL$328.81-15.82(-4.59%)Apple Forecasts Slower Services Growth as AI Costs Rise9:09:51 PM ETCRDO$140.88-10.11(-6.70%)Credo vs. Sandisk: Which Stock Is the Better Buy for 2027?9:00:02 PM ETAAPL$328.81-15.82(-4.59%)Apple may try to increase revenue by doing8:49:52 PM ETCVX$228.21-7.75(-3.29%)Chevron & Exxon Mobil Stocks Retreat From 52-Week Highs: Buy the Dip?8:21:06 PM ETAAPL$328.81-15.82(-4.59%)Apple Q4 Earnings Call Highlights8:14:45 PM ETPLTR$173.00-11.11(-6.03%)What Palantir Technologies (PLTR) Said on Its Q3 Earnings Call8:14:22 PM ETACN$261.99+2.70(+1.05%)Top 25 Attractive Dividend Stocks For November 20268:10:22 PM ETPLTR$173.00-11.11(-6.03%)Here's why Palantir's stock is down despite a ‘bombastic' quarter7:59:00 PM ETAAPL$328.81-15.82(-4.59%)Apple's iPhone business is booming. Here's why the stock is falling anyway.7:52:00 PM ET

IBO · AMEX

Impact BioMedical Inc.

$4.01 +0.21 (+5.53%)

Company overview

Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with applications in oncology, inflammatory disorders, and neurology. The company also offers Laetose technology, derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response caused by sugar alone. It develops functional fragrance formulations, a suite of functional fragrances containing specialized botanical ingredients with applications as antimicrobials and additives in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.

Sector
Healthcare
Industry
Biotechnology
Exchange
AMEX
Market cap
$34.3M
Employees
2
Headquarters
Houston, TX
Website
impactbiomedinc.com
CEO
Frank D. Heuszel
Listed
September 16, 2024
P/E
-3.15
Dividend yield
0.00%

Company financials

Revenue
$39,000
Gross profit
-$680,000
Operating income
-$4.6M
EBITDA
-$13.8M
Net income
-$12.9M
EPS
-$1.27
Total assets
$17.1M
Total debt
$0.00
Gross margin
-1,743.59%
Net margin
-32,969.23%
Earnings yield
-31.70%

Price chart

0.131.943.765.577.38
IBO 1D AMEX O3.80H4.48L3.80C4.01+0.21 (+5.53%)Vol10.29K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
IBOImpact BioMedical Inc. Press release DSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination ACCESS Newswire
IBOImpact BioMedical Inc. Press release Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination ACCESS Newswire
IBOImpact BioMedical Inc. Press release DSS, Inc. Announces Form F-4 Filing in Connection with GlobeNewswire
IBOImpact BioMedical Inc. Press release Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited) GlobeNewswire
IBOImpact BioMedical Inc. Press release CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) GlobeNewswire
IBOImpact BioMedical Inc. Press release Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.) GlobeNewswire
IBOImpact BioMedical Inc. Legal Impact Biomedical Investor News: Rosen Law Firm Encourages Impact Biomedical Inc. Investors to Inquire About Securities Class Action Investigation – IBO Business Wire
IBOImpact BioMedical Inc. Legal Rosen Law Firm Encourages Impact Biomedical Inc. Investors to Inquire About Securities Class Action Investigation – IBO Business Wire
IBOImpact BioMedical Inc. Press release Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans GlobeNewswire
See more
FAQ

Questions about Impact BioMedical Inc.

What does Impact BioMedical Inc. do?
Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with applications in oncology, inflammatory disorders, and neurology. The company also offers Laetose technology, derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response caused by sugar alone. It develops functional fragrance formulations, a suite of functional fragrances containing specialized botanical ingredients with applications as antimicrobials and additives in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.
What is IBO's market cap?
Impact BioMedical Inc. (IBO) is a listed stock with a live quote. The latest market cap on this page is $34.3M.
Where is Impact BioMedical Inc. headquartered?
Impact BioMedical Inc. is headquartered in Houston, TX.
How do I get IBO news from the API?
Call GET /v1/news?tickers=IBO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does IBO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IBO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the IBO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs